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The α-chemokine stromal derived factor 1 (SDF-1), which binds to the CXCR4 and CXCR7 receptors, directs migration and
homing of CXCR4+ hematopoietic stem/progenitor cells (HSPCs) to bone marrow (BM) and plays a crucial role in retention of
these cells in stem cell niches. However, this unique role of SDF-1 has been recently challenged by several observations supporting
SDF-1-CXCR4-independent BM homing. Speciﬁcally, it has been demonstrated that HSPCs respond robustly to some bioactive
lipids, such as sphingosine-1-phosphate (S1P) and ceramide-1-phosphate (C1P), and migrate in response to gradients of certain
extracellular nucleotides, including uridine triphosphate (UTP) and adenosine triphosphate (ATP). Moreover, the responsiveness
ofHSPCstoanSDF-1gradientisenhancedbysomeelementsofinnateimmunity(e.g.,C3complementcascadecleavagefragments
and antimicrobial cationic peptides, such as cathelicidin/LL-37 or β2-defensin) as well as prostaglandin E2 (PGE2). Since all these
factors are upregulated in BM after myeloblative conditioning for transplantation, a more complex picture of homing emerges that
involves several factors supporting, and in some situations even replacing, the SDF-1-CXCR4 axis.
1.Introduction
The α-chemokine stromal derived factor 1 (SDF-1), which
binds to the seven-transmembrane-spanning GαI protein-
coupled receptor CXCR4 is, as has been demonstrated by
several investigators, unique among the family of chemok-
ines, because it directly chemottracts hematopoietic stem/
progenitor cells (HSPCs) [1–3]. Since CXCR4 is expressed
on both long- and short-term repopulating hematopoietic
stemcells(HSCs),aswellashematopoieticprogenitors,SDF-
1 plays an important role in regulating traﬃcking of these
cells and their homing after transplantation to BM, and is
later involved in their active retention in BM stem cell niches
[2–5].
However, while a role for the SDF-1-CXCR4 axis in
retention of HSPCs in BM under steady-state conditions is
undisputed, its exclusive role in stem cell homing has been
challenged by several observations that support the existence
of SDF-1-CXCR4-independent homing [6–8]. In particular,
it has been reported that; (i) CXCR4−/− fetal liver HSPCs
home to BM in an SDF-1-independent manner [6], (ii)
homingofmurineHSPCsmaderefractorytoSDF-1byincu-
bation and coinjection with a CXCR4 receptor antagonist
(AMD3100) is normal or only mildly reduced [7], (iii)
HSPCsinwhichCXCR4hasbeenknockeddownbymeansof
anSDF-1intrakinestrategyareabletoengraft[8],andﬁnally
(iv) myeloablative conditioning for transplantation induces
a highly proteolytic microenvironment in BM that leads to
proteolytic degradation of SDF-1, and thus may severely
attenuate its chemotactic gradient [9].
All this evidence strongly suggests the involvement
of other factors that support homing of HSPCs. In this
paper, we will present cumulative evidence that gradients of
the bioactive sphingophospholipids, such as sphingosine-1-
phosphate (S1P) [10–12] and ceramide-1-phosphate (C1P)2 The Scientiﬁc World Journal
[9, 13, 14], which are products of membrane lipid metabo-
lism, as well as some extracellular nucleotides, including
uridine triphosphate (UTP) and adenosine triphosphate
(ATP) [15–17], play an important role as homing factors for
HSPCs, in addition to SDF-1.
Besides these novel, still underappreciated, homing fac-
tors, several mediators are upregulated in BM conditioned
for transplantation that may positively enhance (prime) the
responsiveness of CXCR4+ HSPCs to an SDF-1 gradient [18,
19]. This is biologically signiﬁcant because, as mentioned
previously, myeloablative conditioning for transplantation
induces a highly proteolytic microenvironment in BM that
leads to proteolytic degradation of SDF-1 and attenuates
its chemotactic gradient [9]. Therefore, all these SDF-1-
CXCR4 axis-sensitizing factors counteract a decrease in the
active SDF-1 gradient. These important priming factors or
modulators of the SDF-1-CXCR4 axis include elements of
innate immunity, such as cleavage fragments of the third
component (C3) of the complement cascade (CC), antimi-
crobial cationic peptides, such as cathelicidin (LL-37) and
β2-defensin, and the eicosanoid prostaglandin E2 (PGE2)
[18–23]. While C3 cleavage fragments (short-lived C3a and
its long-lived derivative desArgC3a), LL-37, and β2-defensin
increase the chemotactic responsiveness of HSPCs to very
shallow SDF-1 gradients by promoting incorporation of
the CXCR4 receptor into membrane lipid rafts, which are
necessary for optimal activation of this receptor [18, 19],
PGE2 upregulates the expression level of this receptor on
HSPCs [22, 24]. In both of these situations, the CXCR4+
HSPCs are able to respond more robustly to SDF-1.
The mechanisms that govern homing of HSPCs to BM
have been the subject of several recent reviews [3, 23–27].
However, here we will focus on novel factors that play a
role in SDF-1-independent BM homing as well as factors
that modulate the activity of the SDF-1-CXCR4 axis and are
involved in homing of HSPCs. What is most important, all
of these factors become upregulated in BM conditioned for
transplantation. Thus, the existence of these factors provides
a novel and complex picture of the homing process that will
be presented and discussed in more detail herein. Figure 1
shows a novel view of HSPC homing in response to SDF-1
and all other chemoattractants involved in this process as
well as the involvement of the SDF-1-CXCR4 axis priming
factors.
2.The Role of SDF-1in
Developmental Migration of HSPCs
andinAdult Hematopoiesis
HSPCs migrate during embryonal development, colonizing
diﬀerent organs where hematopoiesis is initiated. First,
deﬁnitive HSPCs are identiﬁed in the so-called aorta-
gonado-mesonephros (AGM) region, and in the second
trimester of gestation they colonize fetal liver, which is a
major hematopoietic organ at this stage of development [28–
32]. Subsequently, at the beginning of the third trimester
of gestation, HSPCs leave the fetal liver and colonize the
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Figure 1: Homing of HSPCs to BM—the involvement of new
chemotactic and priming factors. Evidence has accumulated that
HSPCs home to BM in response not only to SDF-1 but also
in response to some bioactive lipids (S1P and C1P), as well as
extracellular nucleotides (ATP and UTP). The responsiveness of
HSPCs to an SDF-1 gradient is also positively modulated by several
priming molecules, including peptides of the cationic antimicrobial
peptide (CAMPs) family, and PGE2.
developing BM, which will become a major hematopoietic
organ for the rest of mammalian life [33, 34].
The role of SDF-1 in developmental colonization of the
BM microenvironment was convincingly demonstrated in
SDF-1 and CXCR4 knockout animals [6, 35, 36]. These
studies revealed that murine embryos that lack SDF-1 or
CXCR4 display defects in BM development [36], as well as
other defects in heart, brain, and large-vessel development
that contribute to their lethal phenotype [37–40], and die in
utero.H o w e v e r ,e x c e p tf o rad e f e c ti nB - l y m p h o c y t el i n e a g e
development, they have normal fetal liver hematopoiesis
[36–40].
These studies on SDF-1−/− and CXCR4−/− embryos
revealed two important points. First, colonization of fetal
liver during embryogenesis by AGM-derived HSPCs is not
governed by the SDF-1-CXCR4 axis, and second, SDF-1 is
required for proper migration of HSPCs from fetal liver to
BM. The fact that murine embryos with CXCR4- or SDF-
1-deﬁciency have a normal number of myeloid HSPCs in
fetal liver [6, 37–43], which is colonized by HSPCs migrating
from the AGM region, suggests that this process is mediated
by other chemoattractants. Taking into consideration the
important role of S1P in the development of several tissues
during embryogenesis [44, 45], it is likely that S1P com-
pensates for the SDF-1-CXCR4 deﬁciency in these animals
during developmental migration of HSPCs. This, however,
needs further study. It is also obvious that at some point in
development, HSPCs increase their dependence on SDF-1-
mediated chemotaxis.
Interestingly, as mentioned previously, fetal liver-derived
CXCR4−/− cells may still engraft in lethally irradiated mice
and radioprotect these animals [1, 42, 46]. However, it has
been demonstrated that irradiation chimeras created with
CXCR4−/− HSPCs display some defects in expansion andThe Scientiﬁc World Journal 3
retention of HSPCs in BM [42]. This fact pinpoints the
requirement of the SDF-1-CXCR4 axis not only in retention
of HSPCs in BM but also in proper adult hematopoiesis
and maintenance of a quiescent HSC pool [42, 46]. In this
process, the SDF-1-CXCR4 axis plays a crucial role, together
with other factors, such as Very Late Antigen-4 (VLA-4, also
known as α1β4 integrin), expressed on HSPCs, and Vascular
Adhesion Molecule 1 (VCAM-1, also known as CD106)
expressed in the BM niche [47–49].
SDF-1 has been reported as being expressed in both
osteoblastic and endothelial stem cell niches by osteoblasts
and endothelial cells, respectively [25, 50]. In support of
this ﬁnding, morphological studies revealed that HSCs are
found in the BM microenvironment in contact with the
cells expressing high amounts of SDF-1, which are called
CXCL12-(another name for SDF-1) abundant reticular
(CAR) cells. In particular, CAR cells surround sinusoidal
endothelial cells and are located near the endosteum as
part of the endothelial and osteoblastic niches, respectively
[50,51].SDF-1isalsosecretedbyBMstromalcells,including
nestin+ cells [51, 52].
Expression of SDF-1 is regulated at the transcriptional
level by hypoxia-inducible factor 1 alpha (HIF-1α), which
is upregulated in BM conditioned for transplantation in
response to myeloablative treatment [53]. Nevertheless,
despite upregulation of SDF-1 expression at the mRNA
level, the chemotactic gradient of SDF-1 protein in BM
may be attenuated by several proteolytic enzymes, whose
expressionisinducedinBMaftermyeloablativeconditioning
for transplantation [9]. To ameliorate this eﬀect, several
mechanisms have been identiﬁed that compensate for a
decrease in the SDF-1 gradient, which will be discussed in
the following section.
3. PrimingFactorsThat Responsivenessof
CXCR4+ HSPCsto anSDF-1 Gradient
As mentioned previously, the biological activity of SDF-
1 decreases in BM due to the induction of a proteolytic
microenvironment after conditioning for transplantation, as
seen, for example, after lethal irradiation [9]. In an elegant
study, it has been shown that a few amino acids located at the
N-terminus of SDF-1 that are crucial for the biological activ-
ity of this peptide may be removed by metalloproteinase-
2 (MMP-2) or MMP-9 [54]. This proteolytic processing of
SDF-1 completely inhibits its chemotactic properties [9].
However, as shown in Figure 1, at the same time several
factors have been reported to enhance or sensitize the
responsiveness of HSPCs to an SDF-1 gradient. These factors
include elements of innate immunity, such as cleavage
fragments of C3 [18], cationic antimicrobial peptides, such
as cathelicidin (LL-37) and β2-defensin [19–21], and pros-
taglandin E2 (PGE2) [22–24], a member of the eicosanoid
family.
This priming eﬀect can easily be evaluated in vitro in the
transwell migration assay, where two chambers (an upper
chamber containing the tested cells and a lower chamber
containing chemoattractant) are separated by a porous
membrane that allows transmigration of cells that respond
to the chemotactic gradient (Figure 2). Cells that respond
to this gradient migrate and subsequently accumulate in the
lower chamber. Figures 2 and 3 demonstrate that the chemo-
taxis of HSPCs to a shallow SDF-1 gradient may be signif-
icantly enhanced in the presence of cationic antimicrobial
peptides (CAMPs) [20, 55]. The role of these priming factors
in modulating the SDF-1-CXCR4 axis will be discussed
hereinafter.
3.1. C3 Cleavage Fragments. It has been demonstrated that
the CC, as an evolutionarily old danger-sensing mechanism,
becomes activated during conditioning for transplantation
by radio- and chemotherapy [9]. The third component of
the CC (C3) is an abundant protein in PB plasma (1mg/mL)
and becomes cleaved during CC activation by both classical
and alternative pathways [56] .T h eC 3c l e a v a g el e a d st o
release of liquid-phase cleavage fragments, the C3a and
des−ArgC3a anaphylatoxins [57]. Liquid-phase anaphylatoxin
C3a has a short half-life in plasma and is processed by serum
carboxypeptidase N to des−ArgC3a, which is a long-half-life
cleavage product.
Previous work on C3−/− mice revealed that these animals
are hematologically normal under steady-state conditions
and display a signiﬁcant delay in hematopoietic recovery
from either irradiation or transplantation of wild type
(WT) HSPCs [55, 58, 59]. Speciﬁcally, transplantation of
histocompatiblewildtype(WT)Sca-1+ cellsintoC3−/− mice
resulted in (i) a decrease in day 12 colony forming units in
spleen (CFU-S), (ii) a 5–7-day delay in platelet and leukocyte
recovery, and (iii) a reduced number of BM hematopoietic
clonogenic progenitors at day 16 after transplantation. The
fact that HSPCs from C3−/− mice engrafted normally into
irradiated WT mice suggests that there was a defect in the
hematopoietic environment of C3−/− mice and not some
intrinsic defect of C3−/− mouse-derived HSPCs [18, 58].
Since C3−/− mice cannot activate/cleave C3, the C3 frag-
ments C3a and des−ArgC3a were examined for a role in HSPC
engraftment, and we found that C3a and des−ArgC3a increase
CXCR4incorporationintomembranelipidrafts,thuspoten-
tiating HSPC responsiveness to SDF-1 gradients [59, 60].
Lipid rafts are membrane domains rich in sphingolipids
and cholesterol, which form a lateral assembly in a saturated
glycerophospholipid environment. The raft domains are
known to serve as moving platforms on the cell surface and
are more ordered and resistant to nonionic detergents than
other areas of the membrane [61]. These domains are also
good sites for crosstalk between various cellular signaling
proteins. For example, it has recently been reported that
small guanine nucleotide triphosphatases (GTPases), such
as Rac-1 and Rac-2, which are crucial for engraftment of
hematopoietic cells after transplantation, are associated with
lipid rafts on migrating HSPCs [62–64]. Therefore, since the
CXCR4 receptor is a lipid raft-associated protein, its signal-
ing ability is enhanced if it is incorporated into membrane
lipid rafts, where it can better interact with several signaling
molecules, including the small GTPase Rac-1. This colocal-
ization of CXCR4 and Rac-1 in lipid rafts facilitates GTP
bindingandactivationofRac-1[62,65–67].Thus,thegener-
ation of C3 cleavage fragments in the BM microenvironment4 The Scientiﬁc World Journal
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Figure 2: A priming eﬀect increases the responsiveness of HSPCs to shallow SDF-1 gradients. The overall scheme of chemotactic assays
performed in the transwell system to evaluate the HSPC priming phenomenon (a). In the presence of a priming agent (e.g., cationic
antimicrobial peptides (CAMPs), such as C3a or cathelicidin (LL-37) or β2-defensin), HSPCs respond more robustly to low doses of
SDF-1 [20, 55]. This phenomenon is currently being tested in the clinic, where UCBs are exposed ex vivo to a priming agent (C3a) before
transplantation (b).
may somehow act as a mechanism that increases the respon-
siveness of HSPCs to an SDF-1 gradient when it is degraded
by a proteolytic microenvironment [18]. In C3-deﬁcient
mice this phenomenon is attenuated, explaining why these
animals show delayed engraftment. In this context, increases
in C3a or desArgC3a levels in BM after myeloablative condi-
tioning[18]canbeenvisionedasoneofthemechanismsthat
promote homing of HSPCs (Figures 1–3).
3.2. Cationic Antimicrobial Peptides (CAMPs). CAMPs are
host-defense peptides and are an evolutionarily conserved
component of the innate immune response [68–71]. CAMPs
have been demonstrated to kill bacteria, enveloped viruses,
fungi,andeventransformedorcancerouscellsbutaﬀectonly
the organization and not the viability of the eukaryotic cell
membrane. The selective eﬀects of CAMPs (e.g., eukaryotic
membrane perturbation and prokaryotic killing) are known
to be dependent on characteristics of cell membranes [21,
68–71]. Prokaryote cell membranes are susceptible to strong
electrostatic and hydrophobic interactions with these natural
antibiotics. In contrast, cell membranes of eukaryotic cells,
because of high cholesterol content and weak hydrophobic
interactions with cationic peptides, are more resistant to
the potentially toxic eﬀects of these peptides. One of the
properties of CAMPs that we identiﬁed is their ability to
enhance or prime the responsiveness of cells to an SDF-1
gradient. Interestingly, the C3a and desArgC3a anaphylatoxins
mentioned previously share several properties with CAMPs
[72].
Cathelicidin (LL-37) and β2-defensin belong to the
CAMP family and like C3a, as mentioned before, increase
(positively prime) the responsiveness of HSPCs to an SDF-
1 homing gradient (Figure 1). The molecular explanation of
this phenomenon is the same as in the case of C3a: CAMPs
promote the incorporation of CXCR4 into membrane lipid
rafts [59, 60]. Since, as mentioned before, membrane lipid
rafts assemble together several signaling molecules, incorpo-
rationofCXCR4intolipidraftsfacilitatessignaling,andthus
CXCR4 is activated more eﬃciently in the presence of low
doses of SDF-1.
Further studies are needed to see whether, in addition to
CXCR4, receptors for other chemoattractants of HSPCs that
w ew i l ld i s c u s sh e r e i n a f t e r ,s u c ha sS 1 P ,C 1 P ,A T P ,a n dU T P ,
are also lipid raft-regulated and whether CAMPs enhance
their incorporation into membrane lipid rafts. Of note, it has
been reported that stimulation of S1P receptor type 1 (S1P1)
by its agonist, FY720, increases the responsiveness of HSPCs
to an SDF-1 gradient [73]. However, this phenomenon
probably occurs because of intercellular crosstalk between
CXCR4 and S1P1. Since a receptor for another bioactive
lipid, C1P, has not yet been identiﬁed, it is not clear whether
C1P signaling is also lipid raft-regulated. However, data
indicate that this receptor is expressed on HSPCs and is
sensitive to pertussis toxin, which suggests that, like S1P, it isThe Scientiﬁc World Journal 5
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Figure 3: Cationic antimicrobial peptides (CAMPs) C3a and LL-
37 enhance the responsiveness of murine BM- and human UCB-
derived HSPCs to an SDF-1 gradient: Chemotaxis of murine BM
CFU-GM in response to diﬀerent concentrations of SDF-1 with
and without C3a or LL-37 [20, 55]. Values are the fold increase in
the number of migrated cells compared to the number of migrated
cells in medium alone. Gray bars indicate the presence of LL-37
(2.5μg/mL), cross-hatched bars the presence of C3a (1μg/mL) in
the lower transwell chambers, and black bars indicate PBS only.
The data represent the combined results from three independent
experiments performed in duplicate per group (n = 6).
aG αi protein-coupledreceptor[9].Also,purinergicreceptors
for ATP and UTP are Gαi protein-coupled receptors, and the
possibility of modulation of the activity of these receptors by
C3a, LL-37, or β2-defesin requires further study.
3.3. Prostaglandin E2. In addition to cationic peptides,
prostaglandinE2(PGE2)hasalsobeenpurportedtoincrease
the responsiveness of HSPCs to an SDF-1 gradient [22, 23].
The mechanism of PGE2 inﬂuence on this process, however,
is not lipid raft dependent. As previously reported, PGE2
plays an important role in homing of HSPCs by upregulating
the expression of CXCR4 on the surface of HSPCs, and
this seems to be the most likely mechanism responsible for
increasing chemotaxis in response to an SDF-1 gradient after
pretreatment of HSPCs by PGE2 [22–24, 74]. In further
support of a role for PGE2 in homing, it has recently been
reported that the level of this eicosanoid is signiﬁcantly
upregulatedinBMconditionedforhematopoietictransplan-
tation by lethal irradiation [9].
In addition to the CAMPs and PGE2, hyaluronic acid
[75] and thrombin [76] have also been reported to increase
the responsiveness of HSPCs to an SDF-1 gradient. The exact
mechanism of this priming eﬀect, however, has still not been
elucidated but is most likely mediated by the interaction of
hyaluronic acid with integrin receptors on HSPCs that are
present in lipid rafts. This possibility, however, needs further
study.
4.The BioactiveSphingolipids S1P
andC1P asNovelBM HomingFactors
Sphingophospholipids are important components of cell
membranesandarederivedfromthealiphaticaminoalcohol
sphingosine and its acylated derivative ceramide [27, 77–
79]. Both sphingosine and ceramide are precursors for
the bioactive derivatives sphingosine-1-phosphate (S1P) and
ceramide-1-phosphate (C1P), which strongly chemoattract
HSPCs [9].
S1P is a product of two sphingosine kinases (SK1 and
SK2), is released from cells by a transporter-facilitated
process, and interacts with at least ﬁve Gαi,G 12/13,a n dG q
protein-coupled seven-transmembrane-spanning receptors,
S1P1−5, on the surface of target cells [80, 81]. While S1P1
and S1P3 receptors are most important in promoting the
migration of HSPCs, S1P2 may have an opposing function
[82–84]. Of note, S1P1−5 receptors are rapidly internalized
from the cell surface after binding S1P, which is similar to the
internalization of CXCR4 after binding SDF-1. Accordingly,
S1P has been identiﬁed as a chemottractant for hematopoi-
etic progenitor cells [11, 12, 56], a regulator of traﬃcking of
T lymphocytes between lymphoid organs and PB [85–87], a
factor involved in egress of early B-lymphoid cell progenitors
from BM [88, 89], and a regulator in the traﬃcking of
myeloidprogenitorsbetweenBMandperipheralorgans[89].
We and others have recently demonstrated that S1P plays a
pivotal role in pharmacological mobilization and egress of
HSPCs from BM into peripheral blood (PB) [12, 90]a n d
since it is unregulated in BM conditioned for transplantation
may also probably chemoattract HSPCs to BM [9].
Another bioactive sphingolipid, C1P, is structurally
related to S1P and can be generated by phosphorylation of
ceramide (N-acyl sphingosine) by ceramide kinase (CERK)
[91]. Unlike ceramide (which is often proapoptotic), C1P
has been reported to promote cell growth, survival, and
migration through an unknown receptor-initiated signaling
pathway that is pertussis toxin-sensitive and therefore likely
to involve a Gαi protein-coupled seven-transmembrane-
spanning receptor [14, 92]. The receptors for C1P, however,
have not yet been identiﬁed, though they are clearly distinct
from the known S1P receptors. C1P was initially identiﬁed
as a chemottractant for monocytes [13] and, as has recently
been demonstrated, is also an important, novel, and potent
chemotactic factor involved in the homing of HSPCs to BM
[9].
There are some obvious diﬀerences in biological avail-
ability between these bioactive lipids. While S1P is released
from cells as an important signaling molecule and in
PB is transported by erythrocytes, platelets, albumin, and
high density lipoproteins (HDL), C1P is an intracellular
second messenger released from leaky damaged cells and is
also abundant in plasma in the HDL fraction [14]. While
considering chemotactic gradients of S1P and C1P, one has
to remember that both bioactive lipids must be present in
biological ﬂuids as free, unbound molecules in order to have
a chemotactic potential [9].
Importantly, both S1P and C1P are upregulated in the
BM microenvironment after myeloablative conditioning of6 The Scientiﬁc World Journal
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Figure 4: Responsiveness of murine bone marrow-(BM-) and mobilized peripheral blood-(mPB-) derived HSPCs to SDF-1, S1P, C1P, ATP,
andUTPgradients.ThediﬀerenceinresponsivenessofHSPCsisolatedfromBMversusmPBcouldbeexplainedbyafactthatHSPCsinmPB
are exposed to high concentration of bioactive lipids and extracellular nucleotides, which may lead to downregulation or desensitization of
appropriate receptors. After internalizing these receptors, HSPCs need some time to reexpress functional receptors on the cell surface to
recover their responsiveness to these chemoattractants (data not published, P<0.01).
BM for transplantation [9]. For example, our recent mass
spectrometry (MS) analysis revealed that the major isoforms
of C1P and S1P were detected at higher concentrations in
supernatants harvested from irradiated BM. Taken together
with their potent chemotactic eﬀects, these changes in
concentration of bioactive lipids in BM after myeloablative
conditioning for transplantation suggest that these factors
play an important role in the homing process for HSPCs [9].
However, both bioactive lipids have a limited half-life,
with S1P degraded by several enzymes, such as S1P lyase
(SPL), lipid phosphate phosphatases (LPP1–3), and S1P-
speciﬁc phosphatases (SPP1 and SPP2), while C1P is degrad-
ed by LPP1–3 [93–101]. These pathways may terminate
the eﬀects of S1P and C1P on HSPC migration. Therefore,
further studies are needed to evaluate the changes in kinetics
of the response to S1P and C1P gradients in BM after mye-
loablative treatment.
Furthermore, as mentioned previously, S1P1–5 receptors
and, most likely, still-unknown C1P receptors are down-
regulated on the surface of HSPCs in the presence of S1P
and C1P, respectively [27]. This may explain why HSPCs
harvested from mPB previously exposed to high S1P plasma
concentrations do not respond robustly to S1P and C1P
gradients compared to BM-derived HSPCs (Figure 4). After
internalizing S1P receptors, HSPCs need some time to
reexpress functional receptors on the cell surface to recover
their responsiveness [27].
Finally, in addition to S1P and C1P, we tested other
bioactive lipids. We observed that, in contrast to S1P and
C1P, other members of the bioactive lipid family, such as
lysophosphatidic acid (LPA) and lysophosphatidylcholine
(LPC), do not show chemotactic activity against HSPCs.
Thus, S1P and C1P seem to play a unique role among
evaluated so far members of the family of bioactive lipids.
5.PurinergicNucleotides as
UnderappreciatedHoming Factors
Evidence has accumulated that extracellular-secreted 5 -
nucleotide triphosphates (ATP and UTP) are important bio-
logical mediators involved in cell proliferation, survival, and
cell traﬃcking [102, 103]. In one elegant work, it was shown
thatATPandUTPstimulate,insynergywithsomecytokines,
expansion of HSCs that repopulate BM after transplantation
inanimmunodeﬁcientmousemodel[16].Thesenucleotides
have also been described as chemotactic factors in several
types of cells, including granulocytes and monocytes [15–
17, 104]. Signiﬁcantly, as recently demonstrated for UTP and
to a lesser extent ATP, they modulate traﬃcking of HSCs
and their homing to BM niches [16]. Thus, extracellular
nucleotides may provide a powerful tool to modulate the
function of HSPCs. Interestingly, they display the opposite
eﬀects on human acute myeloblastic leukemia cells to that
which is observed for normal HSCs [105], by inhibiting
proliferation, migration, and engraftment of these cells in
immunodeﬁcient mice.
Both UTP and ATP activate target cells by activat-
ing P2X and P2Y purinergic receptors and P2Y seven-
transmembrane-spanning Gαi-coupled receptors are most
important in mediating the responses of these novel BM
homing factors [17]. Since both ATP and UTP are released
from damaged cells, as seen after myeloablative conditioningThe Scientiﬁc World Journal 7
for transplantation, this explain why they play an important
role together with other factors in the homing of trans-
planted HSPCs (Figure 1).
6. FutureDirections
Evidence has accumulated that the chemotactic responsive-
ness of HSPCs to several homing gradients could be modu-
lated by ex vivo manipulations. One potential strategy is tak-
ing advantage of the HSPC-priming approach. For instance,
the possibility of accelerating or enhancing the homing of
HSPCs by ex vivo exposure of cells in the graft to C3a before
infusion into the patient is currently being evaluated in an
ongoing clinical trial (Masonic Cancer Center, University
of Minnesota). Another interesting molecule that should be
tested in the clinical setting as a potential priming factor
is the cathelicidin LL-37. The advantage of LL-37 is that it
is a physiological factor secreted by BM stromal cells, and,
as shown in Figure 3, is a more potent priming factor than
C3a [20]. Another possible ex vivo manipulation of HSPCs
ingraftingisexposuretoPGE2inordertoupregulateexpres-
sion of CXCR4 to enhance the homing of transplanted cells
[24].Thisstrategyisalsocurrentlybeingevaluatedinclinical
trial. Overall priming strategies would be important in these
clinical situations when a number of HSPCs to be trans-
planted are limited as seen, for example, in UCB transplants.
Furthermore, since HSPCs in the plasma of mobilized
PB and umbilical cord blood are exposed to relatively high
S1P and C1P levels (∼1μM) and the S1P receptors and
most likely C1P ones become internalized mPB-derived
HSPCs, in contrast to BM-derived HSPCs, they respond
weakly to bioactive lipids gradients (Figure 4). To reestablish
expression of these receptors on the surface of HSPCs
and their responsiveness to S1P and C1P gradients, HSPCs
should be exposed to culture medium free of both bioactive
lipids before transplantation. Furthermore, since several
agonists and inhibitors of S1P receptors promoting (S1P1
and S1P3) and inhibiting (S1P2) homing and enzymes
involved in synthesis or degradation of S1P and C1P are
available [44, 82–84], this opens up new possibilities for
positively modulating the responsiveness of HSPCs to BM
S1P and C1P gradients. These tools may lead to more
eﬃcient strategies to improve homing of HSPCs, and these
approaches are currently being tested in murine models.
Since mPB-derived HSPCs show similar relatively weak
responsiveness to ATP and UTP gradients (Figure 4), in
order to reestablish their responsiveness to gradients of these
extracellular nucleotides, HSPCs should be also probably
exposed to culture medium free of these factors before
transplantation.
In addition to aforementioned strategies there are also
other possibilities to manipulate HSPCs to enhance their
homing that were out of scope of this paper. Accordingly,
based on observations that the SDF-1 interaction with
CXCR4+ HSPCs is attenuated by the dipeptidyl-peptidase
CD26, inhibition of CD26 on HSPCs could enhance the
chemotactic responsiveness to an SDF-1 gradient [7]. An-
other interesting strategy is modiﬁcation of adhesion mole-
cules on HSPCs by ex vivo treatment with fucosyltransferase
that increases level of fucosylation of these receptors [106].
As it has been demonstrated human HSPCs after blockage of
CD26 or after fucosylation of adhesion molecules home and
subsequently engraft better on immunodeﬁcient mice [104].
These developments suggest that hematological trans-
plantology can take advantage of basic research into novel
chemoattractants and priming mechanisms that facilitate
homingofHSPCsandtranslatetheseobservationsintomore
eﬃcient clinical protocols.
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